company background image
PHE logo

Cipher Pharmaceuticals DB:PHE Stock Report

Last Price

€9.95

Market Cap

€255.6m

7D

8.2%

1Y

143.9%

Updated

21 Nov, 2024

Data

Company Financials +

Cipher Pharmaceuticals Inc.

DB:PHE Stock Report

Market Cap: €255.6m

Cipher Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cipher Pharmaceuticals
Historical stock prices
Current Share PriceCA$9.95
52 Week HighCA$13.00
52 Week LowCA$3.70
Beta1.17
11 Month Change-9.55%
3 Month Change-5.24%
1 Year Change143.87%
33 Year Change628.94%
5 Year Change1,136.02%
Change since IPO276.89%

Recent News & Updates

Recent updates

Shareholder Returns

PHEDE PharmaceuticalsDE Market
7D8.2%-7.0%-0.4%
1Y143.9%-21.6%7.1%

Return vs Industry: PHE exceeded the German Pharmaceuticals industry which returned -21.6% over the past year.

Return vs Market: PHE exceeded the German Market which returned 7.1% over the past year.

Price Volatility

Is PHE's price volatile compared to industry and market?
PHE volatility
PHE Average Weekly Movement10.4%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: PHE's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: PHE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2000n/aCraig Mullwww.cipherpharma.com

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company’s licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults.

Cipher Pharmaceuticals Inc. Fundamentals Summary

How do Cipher Pharmaceuticals's earnings and revenue compare to its market cap?
PHE fundamental statistics
Market cap€255.62m
Earnings (TTM)€15.03m
Revenue (TTM)€25.09m

17.0x

P/E Ratio

10.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHE income statement (TTM)
RevenueUS$26.46m
Cost of RevenueUS$5.09m
Gross ProfitUS$21.38m
Other ExpensesUS$5.52m
EarningsUS$15.86m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.62
Gross Margin80.78%
Net Profit Margin59.92%
Debt/Equity Ratio40.5%

How did PHE perform over the long term?

See historical performance and comparison